Clinical trial
Amlodipine/Atorvastatin Combination to Reduce the Health Risk of High Blood…
NCT00143234 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00143234 |
|---|---|
| Title | Amlodipine/Atorvastatin Combination to Reduce the Health Risk of High Blood Pressure and High Cholesterol Levels |
| Official title | Clinical Utility of Amlodipine/Atorvastatin to Improve Concomitant Cardiovascular Risk Factors of Hypertension and Dyslipidemia |
| Acronym | GEMINI-AALA |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypertension, Hyperlipidemia |
| Intervention type | Drug |
| Interventions | Amlodipine/atorvastatin single pill |
| Enrollment | 1,825 |
| Start date | May 1, 2004 |
| Completion | Jul 1, 2005 |
| First posted | Sep 2, 2005 |
| Last update posted | Jan 27, 2021 |
| Countries | Argentina, Australia, Brazil, Chile, Guatemala, Hong Kong, India, Indonesia, Israel, Jordan, Kuwait, Lebanon and 15 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: